Neovasc
Neovasc (British Columbia, Canada) currently has the Tiara transcatheter mitral valve replacement device that is implanted in a roughly 20-minute procedure. Earlier this year, the report for its clinical program to test the device showed low leak rates and a 30-day all-cause mortality rate of nearly 10%. The all-cause mortality rate at that point was 9.5% and paravalvular leak levels are reported as absent, trace or mild in 100% of the cases. The device is currently only investigational and is not for sale anywhere.
In May 2016, CardiAQ was awarded $70 million by a jury after finding that Neovasc misappropriated trade secrets in developing the Tiara TMVR. A Massachusetts federal judge awarded CardiAQ an additional $21 million in enhanced damages in November 2016.